MapLight Therapeutics, Inc.
NASDAQMapLight Therapeutics heads into its June 4 earnings report with a wave of fresh analyst conviction — and a stock that has moved sharply in the wrong direction. The analyst story is unusually clean for a clinical-stage biotech. Seven firms have initiated or reiterated Buy ratings since March, with targets clustering between $35 and $48. The most notable move came on June 2, when…
Snapshot as of 3 Jun 2026
MapLight Therapeutics heads into its June 4 earnings report with a wave of fresh analyst conviction — and a stock that has moved sharply in the wrong direction. The analyst story is unusually clean for a clinical-stage…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MPLT — free to start on ORTEX.
Sign up for free →Open MPLT on ORTEX